CGM Frequency and Glycemic Control in People with Type 2 Diabetes Across All Therapies

Initiation and persistence of CGM use (>270 days/year) was associated with a significantly greater A1c reduction at 12 months (-1.52%) versus no CGM, regardless of therapy. Adding a GLP-1, SGLT2i, or insulin with CGM resulted in additional significant A1c reduction. These results highlight the broad benefits of sustained CGM use across different medication types, including for individuals not using insulin.